Recent Updates
Recently added Catalysts

Cimetidine

Phase 3

Bleeding Peptic Ulcer | Small molecule | Other |AstraZeneca PLC|Last Updated: Mar 8, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment239
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01757275High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic UlcerPHASE3 COMPLETED 239Feb 1, 2013Dec 1, 2014Mar 8, 201612 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Rate of Clinically Significant Rebleeding Within 72 Hours
72 hours

Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.

Secondary Endpoints
Rate of Clinically Significant Rebleeding During 7 Days
7 days
Rate of Clinically Significant Rebleeding During 30 Days
30 days
Number of Patients With Endoscopic Re-treatment Within 72 Hours
72 hours
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
EsomeprazoleEXPERIMENTAL -
CimetidineACTIVE_COMPARATOR -
Interventions
NameTypeDescription
Esomeprazole NaDRUGGiven as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
CimetidineDRUGGiven as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
Esomeprazole MgDRUG40 mg tablet once daily for 27 days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * Female or male aged =18 years and =70 years. * Acute upper gastrointestinal bleeding (haematemesis, melaena or haematochezia) or such signs within the last 24 hours as judged by the investigator. * One end...

Countries:China
Unlock Eligibility Criteria